Eli Lilly and Boehringer Ingelheim’s Triple Regimen Receive the US FDA’s Approval for Type 2 Diabetes

 Eli Lilly and Boehringer Ingelheim’s Triple Regimen Receive the US FDA’s Approval for Type 2 Diabetes

Eli Lilly and Boehringer Ingelheim’s Triple Regimen Receive the US FDA’s Approval for Type 2 Diabetes

Shots:

  • The US FDA has approved Trijardy XR which includes Jardiance (empagliflozin), Tradjenta (linagliptin) and metformin hydrochloride extended-release to lower blood sugar in adults with T2D, along with diet and exercise
  • The approval is based on Trijardy XR assessing the bioequivalence of Trijardy XR and their individual components in healthy adults, demonstrating a consistent safety profile of the therapy with their individual components
  • Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride extended-release tablets) is a prescription therapy, available in 4 different dosages to lower the blood sugar level in patients with T2D with CV disease

Click here ­to­ read full press release/ article | Ref: Eli Lilly | Image: Businesswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post